DK2207808T3 - Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse - Google Patents

Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse

Info

Publication number: DK2207808T3
Authority: DK; Denmark
Prior art keywords: nogo; improved; well; binding molecules; pharmaceutical use
Prior art date: 2007-11-02

Application number

DK08843849.4T

Other languages

English (en)

Inventor

Carmen Barske

Stefan Frentzel

Anis Khurso Mir

Martin E Schwab

Alessandra Vitaliti

Original Assignee

Novartis Ag

Univ Zuerich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2008-10-27

Publication date

2013-08-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2207808(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-27 Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag

2013-08-05 Application granted granted Critical

2013-08-05 Publication of DK2207808T3 publication Critical patent/DK2207808T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

DK08843849.4T 2007-11-02 2008-10-27 Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse DK2207808T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US174107P	2007-11-02	2007-11-02
EP07119847		2007-11-02
PCT/EP2008/064501 WO2009056509A1 (en)	2007-11-02	2008-10-27	Improved nogo-a binding molecules and pharmaceutical use thereof

Publications (1)

Publication Number	Publication Date
DK2207808T3 true DK2207808T3 (da)	2013-08-05

Family

ID=39156235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08843849.4T DK2207808T3 (da)	2007-11-02	2008-10-27	Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse

Country Status (31)

Country	Link
US (2)	US8163285B2 (da)
EP (1)	EP2207808B1 (da)
JP (1)	JP5698534B2 (da)
KR (1)	KR101574814B1 (da)
CN (1)	CN101910200B (da)
AR (1)	AR072934A1 (da)
AU (1)	AU2008317724B2 (da)
BR (1)	BRPI0818928B1 (da)
CA (1)	CA2704357C (da)
CL (1)	CL2008003240A1 (da)
CO (1)	CO6270357A2 (da)
CY (1)	CY1114345T1 (da)
DK (1)	DK2207808T3 (da)
ES (1)	ES2425768T3 (da)
HK (1)	HK1143597A1 (da)
HR (1)	HRP20130699T1 (da)
IL (2)	IL205357A (da)
JO (1)	JO2876B1 (da)
MA (1)	MA31805B1 (da)
MX (1)	MX2010004831A (da)
MY (1)	MY149546A (da)
NZ (1)	NZ584911A (da)
PE (1)	PE20090981A1 (da)
PL (1)	PL2207808T3 (da)
PT (1)	PT2207808E (da)
RU (1)	RU2513697C2 (da)
SI (1)	SI2207808T1 (da)
TN (1)	TN2010000199A1 (da)
TW (1)	TWI429656B (da)
WO (1)	WO2009056509A1 (da)
ZA (1)	ZA201002799B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8828390B2 (en)	2010-07-09	2014-09-09	Universitat Zurich	Uses of NOGO-A inhibitors and related methods
JP2015521992A (ja)	2012-07-05	2015-08-03	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン
MX2018005550A (es)	2015-11-03	2019-07-18	Janssen Biotech Inc	Anticuerpos que se unen especificamente a tim-3 y sus usos.
BR112022006534A2 (pt)	2019-10-24	2022-07-05	Novago Therapeutics Ag	Anticorpos anti-nogo-a
WO2024041450A1 (zh) *	2022-08-22	2024-02-29	舒泰神（北京）生物制药股份有限公司	特异性识别Nogo-A的抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
BR9007115A (pt)	1989-02-13	1991-11-26	Schering Ag	Novo trombolitico
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
RU2304585C2 (ru) *	1998-11-06	2007-08-20	Мартин Э. ШВАБ	Очищенный иммуногенный белок, его фрагменты и производные
CN1234730C (zh) *	2001-12-30	2006-01-04	上海中科伍佰豪生物工程有限公司	鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en)	2002-06-07	2009-05-12	Trigen Gmbh	Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en) *	2002-12-10	2003-01-15	Novartis Ag	Organic compound
AU2004220325B2 (en)	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
GB0329684D0 (en) *	2003-12-22	2004-01-28	Glaxo Group Ltd	Method
EP2213684A3 (en)	2003-12-22	2011-05-18	Glaxo Group Limited	Nogo-a antibodies for the treatment of Alzheimer disease
KR100918746B1 (ko)	2004-09-06	2009-09-24	교와 핫꼬 기린 가부시키가이샤	항 ａ３３ 항체
CA2614076A1 (en)	2005-07-05	2007-01-11	Glaxo Group Limited	Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
GB0525662D0 (en) *	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
MX2009000748A (es)	2006-07-18	2009-03-31	Centocor Inc	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
AR069130A1 (es)	2007-11-02	2009-12-30	Novartis Ag	Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko)	2008-10-16	2011-06-09	한국생명공학연구원	Ｔｍｐｒｓｓ４―특이적인 인간항체

2008
- 2008-10-27 US US12/740,777 patent/US8163285B2/en active Active
- 2008-10-27 RU RU2010122044/10A patent/RU2513697C2/ru active
- 2008-10-27 KR KR1020107012080A patent/KR101574814B1/ko active IP Right Grant
- 2008-10-27 AU AU2008317724A patent/AU2008317724B2/en not_active Ceased
- 2008-10-27 WO PCT/EP2008/064501 patent/WO2009056509A1/en active Application Filing
- 2008-10-27 CN CN2008801237017A patent/CN101910200B/zh not_active Expired - Fee Related
- 2008-10-27 CA CA2704357A patent/CA2704357C/en not_active Expired - Fee Related
- 2008-10-27 EP EP08843849.4A patent/EP2207808B1/en active Active
- 2008-10-27 PT PT88438494T patent/PT2207808E/pt unknown
- 2008-10-27 JP JP2010531504A patent/JP5698534B2/ja active Active
- 2008-10-27 PL PL08843849T patent/PL2207808T3/pl unknown
- 2008-10-27 DK DK08843849.4T patent/DK2207808T3/da active
- 2008-10-27 SI SI200831001T patent/SI2207808T1/sl unknown
- 2008-10-27 MY MYPI2010001822A patent/MY149546A/en unknown
- 2008-10-27 MX MX2010004831A patent/MX2010004831A/es active IP Right Grant
- 2008-10-27 BR BRPI0818928-5A patent/BRPI0818928B1/pt not_active IP Right Cessation
- 2008-10-27 ES ES08843849T patent/ES2425768T3/es active Active
- 2008-10-27 NZ NZ584911A patent/NZ584911A/en not_active IP Right Cessation
- 2008-10-30 PE PE2008001859A patent/PE20090981A1/es active IP Right Grant
- 2008-10-30 JO JO2008490A patent/JO2876B1/en active
- 2008-10-30 CL CL2008003240A patent/CL2008003240A1/es unknown
- 2008-10-31 TW TW097142276A patent/TWI429656B/zh not_active IP Right Cessation
2009
- 2009-08-10 AR ARP090103071A patent/AR072934A1/es unknown
2010
- 2010-04-21 ZA ZA2010/02799A patent/ZA201002799B/en unknown
- 2010-04-26 IL IL205357A patent/IL205357A/en active IP Right Grant
- 2010-04-30 CO CO10051504A patent/CO6270357A2/es active IP Right Grant
- 2010-04-30 TN TN2010000199A patent/TN2010000199A1/fr unknown
- 2010-04-30 MA MA32813A patent/MA31805B1/fr unknown
- 2010-10-18 HK HK10109838.5A patent/HK1143597A1/xx not_active IP Right Cessation
2012
- 2012-03-16 US US13/422,642 patent/US8758754B2/en active Active
- 2012-08-30 IL IL221723A patent/IL221723A/en active IP Right Grant
2013
- 2013-07-23 HR HRP20130699AT patent/HRP20130699T1/hr unknown
- 2013-08-08 CY CY20131100676T patent/CY1114345T1/el unknown

Also Published As

Publication number	Publication date
AR072934A1 (es)	2010-09-29
CN101910200A (zh)	2010-12-08
TN2010000199A1 (en)	2011-11-11
TW200934791A (en)	2009-08-16
JP2011502476A (ja)	2011-01-27
KR101574814B1 (ko)	2015-12-04
WO2009056509A1 (en)	2009-05-07
CN101910200B (zh)	2013-12-18
RU2010122044A (ru)	2011-12-10
ZA201002799B (en)	2011-01-26
KR20100100848A (ko)	2010-09-15
US20120171215A1 (en)	2012-07-05
CO6270357A2 (es)	2011-04-20
CA2704357C (en)	2016-06-21
BRPI0818928B1 (pt)	2021-12-07
CL2008003240A1 (es)	2009-06-05
IL221723A0 (en)	2012-10-31
HRP20130699T1 (hr)	2013-11-22
MA31805B1 (fr)	2010-10-01
US8163285B2 (en)	2012-04-24
AU2008317724B2 (en)	2011-06-02
CA2704357A1 (en)	2009-05-07
JP5698534B2 (ja)	2015-04-08
BRPI0818928A2 (pt)	2017-05-16
IL205357A (en)	2014-08-31
US20110027284A1 (en)	2011-02-03
CY1114345T1 (el)	2016-08-31
AU2008317724A1 (en)	2009-05-07
US8758754B2 (en)	2014-06-24
IL221723A (en)	2014-08-31
ES2425768T3 (es)	2013-10-17
SI2207808T1 (sl)	2013-09-30
JO2876B1 (en)	2015-03-15
PT2207808E (pt)	2013-08-26
EP2207808A1 (en)	2010-07-21
IL205357A0 (en)	2010-12-30
MY149546A (en)	2013-09-13
MX2010004831A (es)	2010-05-21
HK1143597A1 (en)	2011-01-07
PL2207808T3 (pl)	2013-11-29
RU2513697C2 (ru)	2014-04-20
NZ584911A (en)	2011-08-26
PE20090981A1 (es)	2009-08-13
EP2207808B1 (en)	2013-05-08
TWI429656B (zh)	2014-03-11

Publication	Publication Date	Title
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
DK3118221T3 (da)	2019-09-23	Proteiner
BRPI0815075A2 (pt)	2015-02-03	Aglutinantes
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0814805A2 (pt)	2014-10-07	Emulsões duplas estáveis
NO20072812L (no)	2008-12-02	Forbedret oreenhet
SE0850135L (sv)	2009-06-14	Häftapparat
BRPI0812803A2 (pt)	2014-12-02	Dessalinização
DK2132326T3 (da)	2012-12-17	Fremgangsmåder
BRPI0814971A2 (pt)	2015-02-03	Proteína
DE112008002590A5 (de)	2010-06-24	Mikroreaktor
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0807004A2 (pt)	2014-04-15	Sal
BRPI0817149A2 (pt)	2015-03-31	Cartucho de tinta
DE112007003225A5 (de)	2009-12-03	Fräsvorrichtung
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
DE602008003849D1 (de)	2011-01-20	Lenkungsdämpfer
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
BRPI0816512A2 (pt)	2015-03-24	Cartucho de tinta
DE602008006408D1 (de)	2011-06-01	Heizvorrichtung
BRPI0920872A2 (pt)	2015-08-18	Mutações relacionadas com heterose induzida.
DK2190865T3 (da)	2014-07-07	Hypoallergent molekyle
ATE475602T1 (de)	2010-08-15	AUSGIEßER
DK2207808T3 (da)	2013-08-05	Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
DE112008002833A5 (de)	2010-12-09	Heizvorrichtung